Supernus Announces Second Quarter 2018 Financial Results and Record Quarterly Revenue
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq fall as megacap tech drags; Iran developments watched
- Oil falls 4% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Supernus Pharma (SUPN) Tops Q2 EPS by 14c, Revenues Miss; Offers FY18 Revenue Outlook Below Consensus
August 7, 2018 4:30 PM EDTSupernus Pharma (NASDAQ: SUPN) reported Q2 EPS of $0.57, $0.14 better than the analyst estimate of $0.43. Revenue for the quarter came in at $99.5 million versus the consensus estimate of $99.86 million.
Total revenue of $99.5 million, a 31% increase over 2017Net product sales of $97.0 million, a 32% increase over... More